Publications by authors named "Brenda Dauer"

Claim this Profile
Q
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Christoph Stephan, Brenda Dauer, Pavel Khaykin, Martin Stuermer, Peter Gute

Curr HIV Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Nils von Hentig, Brenda Dauer, Annette Haberl, Stefan Klauke, Thomas Lutz

Eur J Clin Pharmacol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Martin Stürmer, Brenda Dauer, Manfred Moesch, Annette Haberl, Axel Mueller

Antivir Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
Nils von Hentig, Axel Müller, Carsten Rottmann, Timo Wolf, Thomas Lutz, Brenda Dauer

Antimicrob Agents Chemother· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, Amina Carlebach, Brenda Dauer

J Antimicrob Chemother· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Fiona C Lampe, Jose M Gatell, Schlomo Staszewski, Margaret A Johnson, Christian Pradier, Brenda Dauer

Arch Intern Med· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protease inhibitors: the current status.
Brenda Dauer

J HIV Ther· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.
Colette J Smith, Schlomo Staszewski, Caroline A Sabin, Mark Nelson, Brenda Dauer

J Acquir Immune Defic Syndr· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.
Christoph Stephan, Nils von Hentig, Irene Kourbeti, Brenda Dauer, Manfred Mösch

AIDS· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition of loss of virological response in trials of antiretroviral drugs.
Schlomo Staszewski, Caroline Sabin, Brenda Dauer, Alessandro Cozzi Lepri, Andrew Phillips

AIDS· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis